VERONA PHARMA PLC - ADR (VRNA)

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team....

3 Healthcare Stocks That Have Outperformed Nvidia Since 2022

The healthcare sector is no slouch when it comes to top-performing growth stocks.

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and...

Bullish Two Hundred Day Moving Average Cross - VRNA

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will...

Michael Austwick Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today...

Bullish Two Hundred Day Moving Average Cross - VRNA

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior...

Verona Pharma enters upto $400M debt facility (NASDAQ:VRNA)

Verona Pharma secures debt financing of up to $400M from Oxford Finance and Hercules Capital, enhancing its financial capabilities for growth.

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Strengthens financial flexibility to support the Company’s continued growth...

3 Stocks That Could Be Monster Winners in 2024

Don't be surprised if these three stocks take off in the new year.

Bullish Two Hundred Day Moving Average Cross - VRNA

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

Verona Pharma plc announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023' at the SCRIP awards. ...

Verona Pharma Announces November 2023 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior...

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations...

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage...

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold...

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel,...

Oversold Conditions For Verona Pharma (VRNA)

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

PDUFA Target Action Date of June 26, 2024...

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3...

Christina Ackermann Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023,...

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and...

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage...

Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage...

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

Ensifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal...

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission...

Verona Pharma to Present at Jefferies Healthcare Conference

LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior...

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic...

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May...

Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage...

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage...